GenSight Biologics (DE:G49N) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The REVISE study, officially titled “A Dose-ranging Randomized, Open-label Study Evaluating the Effect of Bilateral Intravitreal Injection of GS010 at Two Dose Levels on Visual Acuity and Retinal Mitochondrial Activity in Patients Affected With ND4 Leber Hereditary Optic Neuropathy,” aims to test how well GenSight’s gene therapy improves vision in this rare eye disease. It focuses on both safety and vision outcomes, which are key to future regulatory and market decisions.
The treatment under review is GS010, also known as Lumevoq or lenadogene nolparvovec, a gene therapy injected into both eyes. It is designed to correct a faulty gene in patients with ND4 Leber Hereditary Optic Neuropathy and potentially restore some visual function.
The study is an interventional Phase 2 trial where patients are randomly assigned to either a high or low dose group. It uses a parallel design with no blinding, meaning both doctors and patients know which dose is given, and the main goal is to treat the disease rather than just observe it.
The trial was first submitted in December 2025, marking the formal launch of this dose-ranging program. The last update was filed on February 27, 2026, signaling that the protocol and recruitment status are current and that the study is still in the recruiting phase.
For investors, this update matters because it advances GenSight’s key asset Lumevoq toward a clearer dosing strategy, which can de-risk later-stage trials and potential approvals. Positive momentum here could support sentiment around DE:G49N, while peers in ophthalmic gene therapy and rare disease, such as other small-cap gene therapy players, may see read-across on regulatory appetite and payer interest.
The REVISE study is currently ongoing and recently updated, with further operational and clinical details available on the ClinicalTrials.gov portal under identifier NCT07303296.
To learn more about DE:G49N’s potential, visit the GenSight Biologics drug pipeline page.